A Phase 2, first-in-class human clinical trial of MTX-463 evaluating safety, pharmacokinetics, and efficacy in patients with idiopathic pulmonary fibrosis (IPF).
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs MTX-463 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 16 Jan 2025 New trial record
- 10 Jan 2025 Mediar Therapeutics announced a global licensing agreement w/ith Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). which is designed to evaluate safety, pharmacokinetics, and efficacy in patients. The trial is expected to initiate in the first half of 2025 and will be conducted by Mediar. Following completion of the Phase 2 study, Lilly will have the right to lead all further clinical development and commercialization of the program.